Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis

Bibliographic Details
Published in:ESMO Open
Main Authors: Norum, Jan, Antonsen, Margareth Aarag, Tollåli, Terje, Al-Shibli, Khalid, Andersen, Gry, Svanqvist, Kristin Helene, Helbekkmo, Nina
Format: Text
Language:English
Published: BMJ Publishing Group 2017
Subjects:
Original Research
Norway
Northern Norway
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/
http://www.ncbi.nlm.nih.gov/pubmed/29209527
https://doi.org/10.1136/esmoopen-2017-000222
id ftpubmed:oai:pubmedcentral.nih.gov:5703383
record_format openpolar
spelling ftpubmed:oai:pubmedcentral.nih.gov:5703383 2023-05-15T17:43:14+02:00 Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis Norum, Jan Antonsen, Margareth Aarag Tollåli, Terje Al-Shibli, Khalid Andersen, Gry Svanqvist, Kristin Helene Helbekkmo, Nina 2017-07-29 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/ http://www.ncbi.nlm.nih.gov/pubmed/29209527 https://doi.org/10.1136/esmoopen-2017-000222 en eng BMJ Publishing Group http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/ http://www.ncbi.nlm.nih.gov/pubmed/29209527 http://dx.doi.org/10.1136/esmoopen-2017-000222 © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ CC-BY-NC Original Research Text 2017 ftpubmed https://doi.org/10.1136/esmoopen-2017-000222 2017-12-10T01:12:51Z Text Northern Norway PubMed Central (PMC) Norway ESMO Open 2 3 e000222
institution Open Polar
collection PubMed Central (PMC)
op_collection_id ftpubmed
language English
topic Original Research
spellingShingle Original Research
Norum, Jan
Antonsen, Margareth Aarag
Tollåli, Terje
Al-Shibli, Khalid
Andersen, Gry
Svanqvist, Kristin Helene
Helbekkmo, Nina
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
topic_facet Original Research
format Text
author Norum, Jan
Antonsen, Margareth Aarag
Tollåli, Terje
Al-Shibli, Khalid
Andersen, Gry
Svanqvist, Kristin Helene
Helbekkmo, Nina
author_facet Norum, Jan
Antonsen, Margareth Aarag
Tollåli, Terje
Al-Shibli, Khalid
Andersen, Gry
Svanqvist, Kristin Helene
Helbekkmo, Nina
author_sort Norum, Jan
title Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
title_short Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
title_full Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
title_fullStr Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
title_full_unstemmed Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
title_sort pembrolizumab as second-line therapy in non-small cell lung cancer in northern norway: budget impact and expected gain—a model-based analysis
publisher BMJ Publishing Group
publishDate 2017
url http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/
http://www.ncbi.nlm.nih.gov/pubmed/29209527
https://doi.org/10.1136/esmoopen-2017-000222
geographic Norway
geographic_facet Norway
genre Northern Norway
genre_facet Northern Norway
op_relation http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/
http://www.ncbi.nlm.nih.gov/pubmed/29209527
http://dx.doi.org/10.1136/esmoopen-2017-000222
op_rights © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
op_rightsnorm CC-BY-NC
op_doi https://doi.org/10.1136/esmoopen-2017-000222
container_title ESMO Open
container_volume 2
container_issue 3
container_start_page e000222
_version_ 1766145260937805824

Similar Items